跳至主要内容
临床试验/NCT01244607
NCT01244607已完成1 期

A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis

Light Chain Bioscience - Novimmune SA0 个研究点目标入组 22 人开始时间: 2010年11月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
22
主要终点
Effect of NI-0801 administration on the severity of the cutaneous response to Nickel challenge as measured using the score system of the DKG (Deutsche Kontakt-Allergie Gruppe).

研究概览

简要总结

The purpose of the study is to assess the effect of a single dose of NI-0801 on the severity of nickel-induced allergic contact dermatitis.

研究设计

研究类型
Interventional
分配方式
Randomized

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥ 18 and ≤ 70 years
  • Either male or a female lacking childbearing potential
  • Previously documented nickel allergy

排除标准

  • Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial or that would prevent subjects from providing informed consent.
  • Known or previous diagnosis of malignancy
  • Known current active tuberculosis or a history of active TB within 12 months of screening
  • Known infection with HIV, Hepatitis B or C

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

NI-0801

Experimental

干预措施: NI-0801 (Drug)

结局指标

主要结局

Effect of NI-0801 administration on the severity of the cutaneous response to Nickel challenge as measured using the score system of the DKG (Deutsche Kontakt-Allergie Gruppe).

次要结局

  • Safety and tolerability of NI-0801 as measured by the incidence and severity of treatment emergent adverse events.

研究者

发起方
Light Chain Bioscience - Novimmune SA
申办方类型
Industry

相似试验